High Net Worth Advisory Group LLC Has $205,000 Holdings in Novo Nordisk A/S (NYSE:NVO)

High Net Worth Advisory Group LLC lowered its position in Novo Nordisk A/S (NYSE:NVO) by 49.4% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 2,384 shares of the company’s stock after selling 2,332 shares during the period. High Net Worth Advisory Group LLC’s holdings in Novo Nordisk A/S were worth $205,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the company. Strategic Investment Solutions Inc. IL acquired a new position in Novo Nordisk A/S in the second quarter valued at $25,000. Daiwa Securities Group Inc. bought a new position in shares of Novo Nordisk A/S in the 3rd quarter worth about $28,000. Capital Performance Advisors LLP acquired a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at about $42,000. Albion Financial Group UT boosted its position in shares of Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after purchasing an additional 278 shares in the last quarter. Finally, Sound Income Strategies LLC grew its stake in Novo Nordisk A/S by 82.1% during the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock worth $46,000 after purchasing an additional 243 shares during the period. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Trading Up 8.4 %

NYSE:NVO opened at $87.94 on Monday. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15. The company has a market cap of $394.65 billion, a PE ratio of 28.46, a PEG ratio of 0.90 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The firm has a 50-day moving average of $95.35 and a 200-day moving average of $114.99.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Buy” and an average target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.